

# 17<sup>TH</sup> EUROPEAN DERMATOLOGY CONGRESS

March 01-03, 2018 | Paris, France

## HeberFERON as a therapeutic option for the treatment of advance and high risk basal cell carcinomas

Iraldo Bello Rivero

Center for Genetic Engineering and Biotechnology, Cuba

**Statement of the Problem:** The incidence of basal cell carcinoma is increasing over the world and is one of the most-costly tumors, however, has lower rate of mortality. These tumors promote high rates of morbidity in face cosmetic locations. IFNs are proteins with anti-tumor properties that have been used in the treatment of non-melanoma skin tumors in an effective and safe way. HeberFERON formulation combines IFNs alpha2b and gamma. HeberFERON was used in several clinical trials in patients with non-melanoma skin tumors.

**Methodology & Theoretical Orientation:** The administration of the IFNs was performed perilesionally using doses from 3.5 to 10.5 MUI, 3 times a week for 3 weeks. PK/PD studies were conducted. All the patients included in the studies gave their consent for participation and the studies were approved by the ethics committees of the participating institutions and CECMED.

**Findings:** Clinical studies of HeberFERON revealed that this formulation generated a faster anti-tumor response than the IFNs separately, as well as a greater number of complete responses, which agrees with the results of the PK/PD that demonstrated a superior biological potency of HeberFERON. The follow-up studies of patients with BCC or SCCS who obtained complete responses (CR) showed that these remain at 5 years free of tumor and that the rate of appearance of new lesions decreased by 8 times. The aesthetic results of these treatments are very favorable and the use of the product is safe. A global analysis of 245 patients with BCC treated with HeberFERON shows a disease control of 98.6% with 61.9% CR and 88.4% objective response. BCC patients received intramuscular treatment with HeberFERON with encouraging results and improved quality of life.

**Conclusion & Significance:** HeberFERON is a new formulation of IFNs with curative capacity for non-melanoma skin tumors, with very favorable aesthetic results, safe and easy to use.

iraldo.bello@cigb.edu.cu